Search
Close this search box.

GAIKER collaborates in developing a tool to assess the impact of advanced materials

The European SUNRISE project will support the development of advanced materials that are safer for people and the environment and more sustainable from the early product development stages to the end of their useful life.

GAIKER Technology Centre is a member of the Basque Research Technology Alliance (BRTA) and one of the 19 partners involved in the European Safe and Sustainable by Design: Integrated Approaches for Impact Assessment of Advanced Materials (SUNRISE) project.

Within the framework of the SUNRISE was launched as part of the European Union's Horizon programme with the aim of developing a tool over the next three years to assess the impact of advanced materials on human health, the environment, society and the economy, in order to be able to make decisions on the safety and sustainability of these materials from the design stage and throughout their life cycles and value chains.

This tool will be presented as a user-friendly web platform and a guide to tackle the challenges of implementing the Safety and Sustainability by Design (SSbD) strategy.

Advanced materials (AdMas) are new materials with improved properties that are specifically designed to perform better than conventional materials (higher strength, durability, lighter, etc.) used for the same purpose.

This research was initiated to analyse whether these materials are safer for people and the environment and more sustainable. GAIKER will primarily be responsible for establishing the methodological blocks for assessing environmental safety and human health (assessment criteria, thresholds, categories and tools). To this end, the Technology Centre will assess the applicability of in vitro models for assessing the safety of advanced materials and will adapt and develop new approach methodologies (NAMs) and integrated approaches to testing and assessment (IATA) that can be used to assess the safety of AdMas for the environment and human health in a cost-effective way while avoiding animal testing.

SUNRISE received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No. 10113732.  

Share on:

Related Posts